Marijuana Dependence Clinical Trial
Official title:
Effect of Baclofen on Marijuana Withdrawal and Relapse
The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.
Only a small percentage of dependent-marijuana smokers who are seeking treatment for their marijuana use are able to achieve sustained abstinence. The objective of this study is to investigate the interaction between marijuana and the potential treatment medication, baclofen, with the direct goal of using this information to improve marijuana treatment outcome. GABAB agonists such as baclofen have been shown to attenuate the self-administration of cocaine, heroin, alcohol and nicotine (see Cousins et al., 2002; Haney et al., 2006). Baclofen also appears to decrease withdrawal symptoms in heroin and alcohol abusers (Akhondzadeh et al., 2000; Addolorato et al., 2000). The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse in our laboratory model. For the purposes of this model, relapse is defined as a return to marijuana use after a period of abstinence. The study will utilize an inpatient/outpatient, counter-balanced design, with each participant maintained on each of three medication conditions for 16 days: placebo and baclofen (60, 90 mg/day). Participants will begin taking capsules during the outpatient phase so that the dose can be incremented up to the maintenance dose prior to the first inpatient day. Further, clinical studies have shown that baclofen is most effective at decreasing cocaine's effects when administered for several weeks. During the inpatient study phases, participants will have the opportunity to self-administer placebo or active marijuana 6 times per day. This study will provide important information of the effect of baclofen as a potential treatment medication for marijuana dependence. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00875836 -
Buspirone Treatment for Marijuana Dependence
|
Phase 4 | |
Completed |
NCT00893269 -
The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep
|
Phase 1 | |
Completed |
NCT00490269 -
Ph1 Marinol Interaction Study - Part 2 - 1
|
Phase 1 | |
Completed |
NCT02579421 -
Hormones and Reduction in Co-users of Marijuana and Nicotine
|
N/A | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01827332 -
Effect of Oxytocin on Craving and Therapy Response
|
N/A | |
Completed |
NCT01335789 -
Effect of Oxytocin on Stress in Marijuana Users
|
N/A | |
Terminated |
NCT00438139 -
Ph1 Marinol Interaction Study - Part 1 - 1
|
Phase 1 | |
Completed |
NCT02955329 -
Vaping THC From Electronic Cigarettes
|
Phase 3 | |
Completed |
NCT02439814 -
Pregnenolone and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT01039415 -
Attempts to Stop/Reduce Marijuana Among Dependent Users
|
N/A | |
Completed |
NCT01347762 -
Nabilone for Cannabis Dependence: A Pilot Study
|
Phase 2/Phase 3 | |
Completed |
NCT00270803 -
The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana
|
N/A | |
Completed |
NCT01020019 -
Combined Pharmacotherapy for Cannabis Dependency
|
Phase 2/Phase 3 | |
Completed |
NCT02030665 -
Marijuana Treatment Project 4
|
N/A | |
Completed |
NCT00107588 -
Marijuana Treatment Project - 3
|
N/A | |
Completed |
NCT02011516 -
Baclofen Effects on Marijuana Dependence
|
Phase 2 | |
Recruiting |
NCT00598052 -
Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
|
N/A | |
Completed |
NCT00374127 -
Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper
|
Phase 2 | |
Completed |
NCT00350649 -
Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
|
Phase 2 |